
## Wayne J G Hellstrom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7796068/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment of Men with Erectile Dysfunction with Transurethral Alprostadil. New England Journal of Medicine, 1997, 336, 1-7.	13.9	622
2	Erectile dysfunction. Nature Reviews Disease Primers, 2016, 2, 16003.	18.1	475
3	Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 Studies. Journal of Urology, 2013, 190, 199-207.	0.2	400
4	An Evidence-Based Definition of Lifelong Premature Ejaculation: Report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation. Journal of Sexual Medicine, 2008, 5, 1590-1606.	0.3	353
5	Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet, The, 2006, 368, 929-937.	6.3	301
6	RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9121-9126.	3.3	297
7	International Society for Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation. Journal of Sexual Medicine, 2010, 7, 2947-2969.	0.3	289
8	Cavernous Neurotomy Causes Hypoxia and Fibrosis in Rat Corpus Cavernosum. Journal of Andrology, 2003, 24, 239-245.	2.0	263
9	Endothelial Dysfunction in Erectile Dysfunction: Role of the Endothelium in Erectile Physiology and Disease. Journal of Andrology, 2003, 24, S17-37.	2.0	222
10	Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. Journal of Andrology, 2002, 23, 763-71.	2.0	206
11	Erectile Dysfunction in Young Men—A Review of the Prevalence and Risk Factors. Sexual Medicine Reviews, 2017, 5, 508-520.	1.5	198
12	Increased Expression of Arginase II in Human Diabetic Corpus Cavernosum: In Diabetic-Associated Erectile Dysfunction. Biochemical and Biophysical Research Communications, 2001, 283, 923-927.	1.0	195
13	Single-Blind, Multicenter, Placebo Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon α-2b for Minimally Invasive Treatment for Peyronie's Disease. Journal of Urology, 2006, 176, 394-398.	0.2	195
14	Effects of Acute Treatment With Tamsulosin Versus Alfuzosin on Ejaculatory Function in Normal Volunteers. Journal of Urology, 2006, 176, 1529-1533.	0.2	192
15	Bother and Distress Associated with Peyronie's Disease: Validation of the Peyronie's Disease Questionnaire. Journal of Urology, 2013, 190, 627-634.	0.2	176
16	An Evidence-Based Unified Definition of Lifelong and Acquired Premature Ejaculation: Report of the Second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. Sexual Medicine, 2014, 2, 41-59.	0.9	174
17	Paediatric and adult-onset male hypogonadism. Nature Reviews Disease Primers, 2019, 5, 38.	18.1	153
18	Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology, 2003, 61, 8-14.	0.5	136

#	Article	IF	CITATIONS
19	Standardization of Vascular Assessment of Erectile Dysfunction. Journal of Sexual Medicine, 2013, 10, 120-129.	0.3	136
20	Gene Transfer of Endothelial Nitric Oxide Synthase Partially Restores Nitric Oxide Synthesis and Erectile Function in Streptozotocin Diabetic Rats. Journal of Urology, 2003, 169, 1911-1917.	0.2	133
21	Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1278-H1290.	1.5	133
22	Tadalafil has No Detrimental Effect on Human Spermatogenesis or Reproductive Hormones. Journal of Urology, 2003, 170, 887-891.	0.2	128
23	Implants, Mechanical Devices, and Vascular Surgery for Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 501-523.	0.3	127
24	An evidenceâ€based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU International, 2008, 102, 338-350.	1.3	125
25	The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. Journal of Sexual Medicine, 2015, 12, 1660-1686.	0.3	119
26	ORIGINAL RESEARCH—BASIC SCIENCE: Superoxide Anion Production in the Rat Penis Impairs Erectile Function in Diabetes: Influence of In Vivo Extracellular Superoxide Dismutase Gene Therapy. Journal of Sexual Medicine, 2005, 2, 187-198.	0.3	118
27	The Hydrophilicâ€Coated Inflatable Penile Prosthesis: 1â€Year Experience. Journal of Sexual Medicine, 2004, 1, 221-224.	0.3	116
28	APPLICATION OF PERICARDIAL GRAFT IN THE SURGICAL MANAGEMENT OF PEYRONIE'S DISEASE. Journal of Urology, 2000, 163, 1445-1447.	0.2	109
29	Reproductive capacity of the nucleus of the male gamete after completion of meiosis. Journal of Assisted Reproduction and Genetics, 1994, 11, 335-341.	1.2	107
30	A RAT MODEL OF PEYRONIE'S DISEASE ASSOCIATED WITH A DECREASE IN ERECTILE ACTIVITY AND AN INCREASE IN INDUCIBLE NITRIC OXIDE SYNTHASE PROTEIN EXPRESSION. Journal of Urology, 2000, 163, 1992-1998.	0.2	103
31	Semen and Sperm Reference Ranges for Men 45 Years of Age and Older. Journal of Andrology, 2006, 27, 421-428.	2.0	103
32	Gene transfer of extracellular SOD to the penis reduces O 2 â^' • and improves erectile function in aged rats. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1408-H1421.	1.5	101
33	EFFICACY AND SAFETY OF TRANSURETHRAL ALPROSTADIL IN PATIENTS WITH ERECTILE DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1998, 160, 1325-1328.	0.2	100
34	Infection Retardant Coated Inflatable Penile Prostheses Decrease the Incidence of Infection: A Systematic Review and Meta-Analysis. Journal of Urology, 2012, 188, 1855-1860.	0.2	100
35	Pharmacotherapy for erectile dysfunction. Trends in Pharmacological Sciences, 2000, 21, 484-489.	4.0	97
36	Post-SSRI Sexual Dysfunction: A Literature Review. Sexual Medicine Reviews, 2018, 6, 29-34.	1.5	94

3

#	Article	IF	CITATIONS
37	Patient and partner satisfaction and long-term results after surgical treatment for Peyronie's disease. Urology, 2003, 62, 105-109.	0.5	89
38	Transplantation of Nonhematopoietic Adult Bone Marrow Stem/Progenitor Cells Isolated by p75 Nerve Growth Factor Receptor Into the Penis Rescues Erectile Function in a Rat Model of Cavernous Nerve Injury. Journal of Urology, 2010, 184, 1560-1566.	0.2	87
39	Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1340-H1351.	1.5	85
40	Newer Modalities in the Diagnosis and Treatment of Ejaculatory Duct Obstruction. Journal of Urology, 1993, 150, 1150-1154.	0.2	84
41	Critical analysis of surgery for Peyronie's disease. Current Opinion in Urology, 2004, 14, 381-388.	0.9	83
42	A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology, 1996, 48, 851-856.	0.5	80
43	The pharmacological treatment of premature ejaculation. BJU International, 2008, 102, 668-675.	1.3	80
44	Gene Transfer of Prepro-Calcitonin Gene-Related Peptide Restores Erectile Function in the Aged Rat1. Biology of Reproduction, 2001, 65, 1371-1377.	1.2	79
45	Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease. Andrology, 2014, 2, 244-251.	1.9	75
46	Adult-Onset Hypogonadism. Mayo Clinic Proceedings, 2016, 91, 908-926.	1.4	74
47	Penile Prosthesis Complications: Planning, Prevention, and Decision Making. Sexual Medicine Reviews, 2019, 7, 349-359.	1.5	73
48	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opinion on Investigational Drugs, 2010, 19, 1427-1437.	1.9	72
49	Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opinion on Pharmacotherapy, 2010, 11, 1109-1122.	0.9	72
50	Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opinion on Drug Safety, 2013, 12, 81-90.	1.0	71
51	Managing the Difficult Penile Prosthesis Patient. Journal of Sexual Medicine, 2013, 10, 893-907.	0.3	69
52	5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection. Journal of Sexual Medicine, 2008, 5, 2917-2924.	0.3	68
53	The pathophysiology of acquired premature ejaculation. Translational Andrology and Urology, 2016, 5, 434-449.	0.6	67
54	Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options. Expert Opinion on Pharmacotherapy, 2011, 12, 931-944.	0.9	66

#	Article	IF	CITATIONS
55	Modifying Risk Factors in the Management of Erectile Dysfunction: A Review. World Journal of Men?s Health, 2016, 34, 89.	1.7	64
56	Current updates on laboratory techniques for the diagnosis of male reproductive failure. Asian Journal of Andrology, 2016, 18, 392.	0.8	63
57	Contemporary Review of Grafting Techniques for the Surgical Treatment of Peyronie's Disease. Sexual Medicine Reviews, 2017, 5, 544-552.	1.5	63
58	The Penile Implant for Erectile Dysfunction. Journal of Sexual Medicine, 2004, 1, 98-109.	0.3	62
59	Understanding the course of Peyronie's disease. International Journal of Clinical Practice, 2013, 67, 781-788.	0.8	62
60	The Impact of Thyroid Disease on Sexual Dysfunction in Men and Women. Sexual Medicine Reviews, 2019, 7, 57-70.	1.5	61
61	Multipotent Stromal Cell Therapy for Cavernous Nerve Injury-Induced Erectile Dysfunction. Journal of Sexual Medicine, 2012, 9, 385-403.	0.3	60
62	Long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Review of Medical Devices, 2013, 10, 353-366.	1.4	60
63	Medical Management of Peyronie's Disease. Journal of Andrology, 2009, 30, 397-405.	2.0	59
64	The Effects of Chronic 5-Alpha-Reductase Inhibitor (Dutasteride) Treatment on Rat Erectile Function. Journal of Sexual Medicine, 2011, 8, 3066-3074.	0.3	58
65	Long-Term Revision Rate Due to Infection in Hydrophilic-Coated Inflatable Penile Prostheses: 11-Year Follow-up. Journal of Sexual Medicine, 2012, 9, 2182-2186.	0.3	58
66	Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochemical and Biophysical Research Communications, 2002, 298, 427-432.	1.0	57
67	An Evaluation of Semen Characteristics in Men 45 Years of Age or Older after Daily Dosing with Tadalafil 20mg: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, 9-Month Study. European Urology, 2008, 53, 1058-1065.	0.9	57
68	Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2090-2095.	3.3	57
69	The Effect of Duration of Penile Traction Therapy in Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease. Journal of Urology, 2015, 194, 754-758.	0.2	57
70	Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. Sexual Medicine Reviews, 2015, 3, 101-112.	1.5	56
71	Update on erectile dysfunction in prostate cancer patients. Current Opinion in Urology, 2006, 16, 186-195.	0.9	53
72	Relationship Between the Severity of Penile Curvature and the Presence of Comorbidities in Men With Peyronie's Disease. Journal of Urology, 2004, 171, 775-779.	0.2	52

#	Article	IF	CITATIONS
73	The Impact of Intralesional Interferon αâ€2b Injection Therapy on Penile Hemodynamics in Men with Peyronie's Disease. Journal of Sexual Medicine, 2005, 2, 709-715.	0.3	52
74	Current Concepts in the Management of Erectile Dysfunction in Men with Prostate Cancer. Clinical Prostate Cancer, 2004, 3, 87-92.	2.1	50
75	Intralesional Injection of Interferon-α2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location. Journal of Urology, 2015, 194, 1704-1707.	0.2	49
76	Safety and Efficacy of Collagenase <i>Clostridium histolyticum</i> in the Treatment of Acute-Phase Peyronie's Disease. Journal of Sexual Medicine, 2017, 14, 1220-1225.	0.3	49
77	Outcomes of Intralesional Interferon-α2B for the Treatment of Peyronie Disease. Journal of Urology, 2013, 190, 2194-2199.	0.2	48
78	Treatment of Peyronie's Disease: 2012 Update. Current Urology Reports, 2011, 12, 444-452.	1.0	45
79	INTRACAVERNOSAL INJECTION AND INTRAURETHRAL THERAPY FOR ERECTILE DYSFUNCTION. Urologic Clinics of North America, 2001, 28, 343-354.	0.8	44
80	STRATIFICATION OF PENILE VASCULAR PATHOLOGIES IN PATIENTS WITH PEYRONIE'S DISEASE AND IN MEN WITH ERECTILE DYSFUNCTION ACCORDING TO AGE: A COMPARATIVE STUDY. Journal of Urology, 2004, 172, 259-262.	0.2	44
81	Management of sildenafil treatment failures. Current Opinion in Urology, 2006, 16, 449-459.	0.9	44
82	Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy with Collagenase Clostridium Histolyticum for Peyronie's Disease. Journal of Sexual Medicine, 2016, 13, 684-689.	0.3	44
83	The Effect of Vascular Risk Factors on Penile Vascular Status in Men With Erectile Dysfunction. Journal of Urology, 2007, 178, 2516-2520.	0.2	43
84	Baseline Characteristics from an Ongoing Phase 3 Study of Collagenase Clostridium Histolyticum in Patients with Peyronie's Disease. Journal of Sexual Medicine, 2013, 10, 2822-2831.	0.3	43
85	Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients With Peyronie's Disease. Urology, 2017, 100, 125-130.	0.5	43
86	Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Therapeutics and Clinical Risk Management, 2007, 3, 277-289.	0.9	42
87	Emerging treatments for premature ejaculation: focus on dapoxetine. Neuropsychiatric Disease and Treatment, 2009, 5, 37.	1.0	41
88	Therapeutic advances in the treatment of Peyronie's disease. Andrology, 2015, 3, 650-660.	1.9	40
89	The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. Sexual Medicine Reviews, 2016, 4, 74-84.	1.5	40
90	Gene Therapy for Erectile Dysfunction: Fact or Fiction?. European Urology, 2006, 50, 1208-1222.	0.9	39

#	Article	IF	CITATIONS
91	Ejaculatory Dysfunction and Its Association With Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia and BPH Treatment. Urology, 2009, 74, 15-21.	0.5	39
92	Intralesional Interferon-α-2B Injections for the Treatment of Peyronie's Disease. Southern Medical Journal, 2004, 97, 42-46.	0.3	39
93	Side Effects of 5â€Alpha Reductase Inhibitors: A Comprehensive Review. Sexual Medicine Reviews, 2013, 1, 24-41.	1.5	38
94	The dangers of sexual enhancement supplements and counterfeit drugs to "treat―erectile dysfunction. Translational Andrology and Urology, 2017, 6, 12-19.	0.6	36
95	Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1?. BJU International, 2007, 99, 1488-1494.	1.3	35
96	Effects of Alfuzosin and Tamsulosin on Sperm Parameters in Healthy Men: Results of a Shortâ€īerm, Randomized, Doubleâ€Blind, Placeboâ€Controlled, Crossover Study. Journal of Andrology, 2009, 30, 469-474.	2.0	35
97	Transforming Growth Factor-β1 Induced Urethral Fibrosis in a Rat Model. Journal of Urology, 2015, 194, 820-827.	0.2	35
98	POTENTIATION OF ERECTILE RESPONSE AND cAMP ACCUMULATION BY COMBINATION OF PROSTAGLANDIN E 1 AND ROLIPRAM, A SELECTIVE INHIBITOR OF THE TYPE 4 PHOSPHODIESTERASE (PDE 4). Journal of Urology, 1999, 162, 1848-1855.	0.2	34
99	Pharmacological Management of Peyronie???s Disease. Drugs, 2007, 67, 527-545.	4.9	34
100	Update on treatments for premature ejaculation. International Journal of Clinical Practice, 2011, 65, 16-26.	0.8	34
101	Review of Management Options for Patients With Atypical Peyronie's Disease. Sexual Medicine Reviews, 2017, 5, 211-221.	1.5	34
102	THE RELATIONSHIP BETWEEN THE TYPE OF PENILE ABNORMALITY AND PENILE VASCULAR STATUS IN PATIENTS WITH PEYRONIE'S DISEASE. Journal of Urology, 2005, 174, 632-635.	0.2	33
103	The link between penile hypersensitivity and premature ejaculation. BJU International, 2011, 107, 452-457.	1.3	33
104	Erectile dysfunction in urethral stricture and pelvic fracture urethral injury patients: diagnosis, treatment, and outcomes. Andrology, 2015, 3, 443-449.	1.9	33
105	Multi-institutional Prospective Analysis of Intralesional Injection of Collagenase Clostridium Histolyticum, Tunical Plication, and Partial Plaque Excision and Grafting for the Management of Peyronie's Disease. Urology, 2018, 120, 138-142.	0.5	33
106	Premature ejaculation: current and future treatments. Asian Journal of Andrology, 2008, 10, 102-109.	0.8	32
107	Device Survival after Primary Implantation of an Artificial Urinary Sphincter for Male Stress Urinary Incontinence. Journal of Urology, 2017, 197, 759-765.	0.2	32
108	Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis. Journal of Urology, 2019, 201, 777-782.	0.2	32

#	Article	IF	CITATIONS
109	Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology, 2004, 64, 1187-1195.	0.5	31
110	Penile calciphylaxis. Urology, 1997, 50, 622-624.	0.5	30
111	Testicular-sparing surgery: a reasonable option in selected patients with testicular lesions. BJU International, 2003, 91, 337-340.	1.3	30
112	Current and Future Pharmacotherapies of Premature Ejaculation. Journal of Sexual Medicine, 2006, 3, 332-341.	0.3	30
113	History, Contemporary Outcomes, and Future of Penile Prostheses: A Review of the Literature. Sexual Medicine Reviews, 2013, 1, 150-163.	1.5	30
114	Contemporary Review of Artificial Urinary Sphincters for Male Stress Urinary Incontinence. Sexual Medicine Reviews, 2016, 4, 157-166.	1.5	30
115	Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. Urology, 2017, 107, 155-160.	0.5	30
116	Vardenafil: A new approach to the treatment of erectile dysfunction. Current Urology Reports, 2003, 4, 479-487.	1.0	29
117	POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITION PRESERVES ERECTILE FUNCTION IN RATS AFTER CAVERNOUS NERVE INJURY. Journal of Urology, 2005, 174, 2054-2059.	0.2	29
118	Incomplete Recovery of Erectile Function in Rat after Discontinuation of Dual 5â€Alpha Reductase Inhibitor Therapy. Journal of Sexual Medicine, 2012, 9, 1773-1781.	0.3	29
119	Emerging drugs for the treatment of erectile dysfunction. Expert Opinion on Emerging Drugs, 2015, 20, 263-275.	1.0	29
120	Collagenase Clostridium histolyticum (Xiaflex) for the Treatment of Urethral Stricture Disease in a Rat Model of Urethral Fibrosis. Urology, 2015, 86, 647.e1-647.e6.	0.5	29
121	Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact. Sexual Medicine Reviews, 2018, 6, 143-156.	1.5	29
122	Review of Management Options for Active-Phase Peyronie's Disease. Sexual Medicine Reviews, 2019, 7, 329-337.	1.5	29
123	Chronic inhibition of nitricâ€oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil. BJU International, 2010, 106, 78-83.	1.3	28
124	Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study. Journal of Urology, 2015, 194, 485-492.	0.2	28
125	Self-report and Clinical Response to Peyronie's Disease Treatment: Peyronie's Disease Questionnaire Results From 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies. Urology, 2015, 86, 291-299.	0.5	28
126	Current Perspectives on Stem Cell Therapy for Erectile Dysfunction. Sexual Medicine Reviews, 2016, 4, 247-256.	1.5	28

#	Article	IF	CITATIONS
127	Antimicrobial activity of antibiotic-soaked, Resist™-coated Bioflex®. International Journal of Impotence Research, 2003, 15, 18-21.	1.0	27
128	Endothelial Nitric Oxide Synthase Gene Therapy for Erectile Dysfunction. Current Pharmaceutical Design, 2005, 11, 4059-4067.	0.9	27
129	A phase <scp>II</scp> , singleâ€blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. BJU International, 2013, 111, 137-147.	1.3	27
130	Intracorporeal Robot-Assisted Microsurgical Vasovasostomy for the Treatment of Bilateral Vasal Obstruction Occurring Following Bilateral Inguinal Hernia Repairs with Mesh Placement. Journal of Urology, 2014, 191, 1120-1125.	0.2	26
131	Strategies for Penile Prosthesis Placement in Peyronie's Disease and Corporal Fibrosis. Current Urology Reports, 2015, 16, 21.	1.0	26
132	Post-Orgasmic Illness Syndrome: A Review. Sexual Medicine Reviews, 2018, 6, 11-15.	1.5	26
133	MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. Advances in Therapy, 2022, 39, 3403-3422.	1.3	26
134	Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction. Current Pharmaceutical Design, 2010, 16, 1619-1633.	0.9	25
135	Sexual Dysfunction Following Radical Prostatectomy. Journal of Andrology, 2012, 33, 1143-1154.	2.0	25
136	Andrianne Mini-Jupette Graft at the Time of Inflatable Penile Prosthesis Placement for the Management of Post-Prostatectomy Climacturia and Minimal Urinary Incontinence. Journal of Sexual Medicine, 2018, 15, 789-796.	0.3	25
137	Role of Penile Prosthesis in Priapism: A Review. World Journal of Men?s Health, 2018, 36, 4.	1.7	25
138	Optimizing Nitric Oxide Production by Time Dependent L-Arginine Administration in Isolated Human Corpus Cavernosum. Journal of Urology, 2007, 178, 1543-1548.	0.2	24
139	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. International Journal of Clinical Practice, 2007, 61, 1547-1554.	0.8	24
140	Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review. International Urology and Nephrology, 2012, 44, 61-70.	0.6	24
141	Advances in stem cell therapy for erectile dysfunction. Expert Opinion on Biological Therapy, 2018, 18, 1137-1150.	1.4	24
142	The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction. Journal of Sexual Medicine, 2018, 15, 1280-1292.	0.3	24
143	Review of Erectile Dysfunction in Diabetic Animal Models. Current Diabetes Reviews, 2014, 10, 61-73.	0.6	24
144	The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment. BJU International, 2004, 94, 429-432.	1.3	23

#	Article	IF	CITATIONS
145	Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. BJU International, 2008, 102, 1651-1657.	1.3	23
146	Clinical Use of Aromatase Inhibitors in Adult Males. Sexual Medicine Reviews, 2014, 2, 79-90.	1.5	23
147	Role of genitourinary inflammation in infertility: synergistic effect of lipopolysaccharide and interferon-gamma on human spermatozoa. Journal of Developmental and Physical Disabilities, 2001, 24, 136-141.	3.6	22
148	Effect of adipose tissue-derived stem cell injection in a rat model of urethral fibrosis. Canadian Urological Association Journal, 2016, 10, 175.	0.3	22
149	Adipose Tissue-Derived Stem Cells for the Treatment of Erectile Dysfunction. Current Urology Reports, 2016, 17, 14.	1.0	22
150	Peyronie's disease: Advances in basic science and pathophysiology. Current Urology Reports, 2000, 1, 297-301.	1.0	21
151	Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?. BJU International, 2016, 118, 464-474.	1.3	21
152	Surgical approaches for advanced Peyronie's disease patients. International Journal of Impotence Research, 2003, 15, S121-S124.	1.0	20
153	The Effect of Adjunct Mechanical Traction on Penile Length in Men Undergoing Primary Treatment for Peyronie's Disease: A Systematic Review and Meta-analysis. Urology, 2018, 122, 110-115.	0.5	20
154	Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opinion on Investigational Drugs, 2008, 17, 855-864.	1.9	19
155	Efficacy of Pioglitazone on Erectile Function Recovery in a Rat Model of Cavernous Nerve Injury. Urology, 2014, 84, 1122-1127.	0.5	19
156	Update on Medical Management of Peyronie's Disease. Current Urology Reports, 2014, 15, 415.	1.0	19
157	Bilateral Renal Parenchymal Malacoplakia: A Case Report. Journal of Urology, 1992, 147, 115-117.	0.2	18
158	Clinical applications of centrally acting agents in male sexual dysfunction. International Journal of Impotence Research, 2008, 20, S17-S23.	1.0	18
159	Successful Treatment of Residual Curvature in Peyronie Disease in Men Previously Treated With Intralesional Collagenase Clostridium Histolyticum. Urology, 2017, 110, 110-113.	O.5	18
160	Bilateral Cavernous Nerve Crush Injury in the Rat Model: A Comparative Review of Pharmacologic Interventions. Sexual Medicine Reviews, 2018, 6, 234-241.	1.5	18
161	Unintended Consequences: A Review of Pharmacologically-Induced Priapism. Sexual Medicine Reviews, 2019, 7, 283-292.	1.5	18
162	Guide to Drug Therapy for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Obstruction. Drugs, 2008, 68, 209-229.	4.9	17

#	Article	IF	CITATIONS
163	Hypogonadism, ADAM, and hormone replacement. Therapeutic Advances in Urology, 2010, 2, 99-104.	0.9	17
164	Amelioration of gentamicin nephrotoxicity by green tea extract in uninephrectomized rats as a model of progressive renal failure. Renal Failure, 2010, 32, 1210-1215.	0.8	16
165	Adolescent varicocoele management controversies. Andrology, 2013, 1, 109-115.	1.9	16
166	Cyclingâ€Related Sexual Dysfunction in Men and Women: A Review. Sexual Medicine Reviews, 2014, 2, 93-101.	1.5	16
167	Overview of potential molecular targets for hydrogen sulfide: A new strategy for treating erectile dysfunction. Nitric Oxide - Biology and Chemistry, 2015, 50, 65-78.	1.2	16
168	Penile Stretching as a Treatment for Peyronie's Disease: A Review. Sexual Medicine Reviews, 2019, 7, 508-515.	1.5	16
169	Antisperm Antibodies Bind With Different Patterns to Sperm of Different Men. Journal of Urology, 1987, 138, 895-898.	0.2	15
170	Localization of Peripheral Dopamine D1 and D2 Receptors in Rat and Human Seminal Vesicles. Journal of Andrology, 2002, 23, 114-120.	2.0	15
171	Vardenafil in Patients With Erectile Dysfunction: Achieving Treatment Optimization. Journal of Andrology, 2005, 26, 604-609.	2.0	15
172	RhoA/Rhoâ€Kinase as a Therapeutic Target for the Male Urogenital Tract. Journal of Sexual Medicine, 2011, 8, 675-687.	0.3	15
173	Survey of patient and partner satisfaction following collagenase <i>Clostridium histolyticum</i> treatment for Peyronie's disease. Andrology, 2017, 5, 274-277.	1.9	15
174	Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute Phase Peyronie's Disease: A Multi-institutional Analysis. Urology, 2020, 145, 147-151.	0.5	15
175	Testosterone positively regulates functional responses and nitric oxide expression in the isolated human corpus cavernosum. Andrology, 2020, 8, 1824-1833.	1.9	15
176	Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction. Expert Opinion on Pharmacotherapy, 2004, 5, 923-932.	0.9	14
177	Peripheral Mechanisms of Erectile Dysfunction in a Rat Model of Chronic Cocaine Use. European Urology, 2007, 52, 555-564.	0.9	14
178	A review of current progress in gene and stem cell therapy for erectile dysfunction. Expert Opinion on Biological Therapy, 2008, 8, 1521-1538.	1.4	14
179	The pre-treatment prevalence and types of sexual dysfunction among patients diagnosed with prostate cancer. Andrology, 2013, 1, 859-863.	1.9	14
180	Avanafil for the treatment of erectile dysfunction. Expert Review of Clinical Pharmacology, 2016, 9, 1163-1170.	1.3	14

#	Article	IF	CITATIONS
181	Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option. World Journal of Men?s Health, 2017, 35, 134.	1.7	14
182	An update on: long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Review of Medical Devices, 2019, 16, 281-286.	1.4	14
183	Current concepts in ejaculatory dysfunction. Reviews in Urology, 2006, 8 Suppl 4, S18-25.	0.9	14
184	Sex and the Infertile Male. Seminars in Reproductive Medicine, 2009, 27, 186-190.	0.5	13
185	Imatinib Mesylate (Gleevec) Induces HumanÂCorpus Cavernosum Relaxation byÂInhibiting Receptor Tyrosine Kinases (RTKs):Âldentification of New RTK Targets. Urology, 2013, 82, 745.e11-745.e16.	0.5	13
186	Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. Research and Reports in Urology, 2016, Volume 8, 123-131.	0.6	13
187	Imatinib Mesylate (Gleevec) as Protein-tyrosine Kinase Inhibitor Elicits Smooth Muscle Relaxation in Isolated Human Prostatic Tissue. Urology, 2011, 78, 968.e1-968.e6.	0.5	12
188	Comparative Analysis of Tunical Plication vs. Intralesional Injection Therapy for Ventral Peyronie's Disease. Journal of Sexual Medicine, 2015, 12, 2492-2498.	0.3	12
189	Male Orgasmic Dysfunction Post-Radical Pelvic Surgery. Sexual Medicine Reviews, 2018, 6, 429-437.	1.5	12
190	Review of Intralesional Collagenase Clostridium Histolyticum Injection Therapy and Related Combination Therapies in the Treatment of Peyronie's Disease (an Update). Sexual Medicine Reviews, 2021, 9, 340-349.	1.5	12
191	EFFECTS OF ALPROSTADIL AND PRAZOSIN ON MOTILITY, VIABILITY AND MEMBRANE INTEGRITY OF HUMAN SPERM. Journal of Urology, 1998, 159, 1559-1562.	0.2	11
192	A critical analysis of the surgical outcomes for the treatment of Peyronie's disease. Arab Journal of Urology Arab Association of Urology, 2013, 11, 284-293.	0.7	11
193	Current and emerging treatment options for Peyronie's disease. Research and Reports in Urology, 2013, 5, 17.	0.6	11
194	Failure to attain stretched penile length after intracavernosal injection of a vasodilator agent is predictive of veno-occlusive dysfunction on penile duplex Doppler ultrasonography. Andrology, 2015, 3, 919-923.	1.9	11
195	Pregabalin Does Not Affect Sperm Production in Healthy Volunteers: A Randomized, Doubleâ€blind, Placeboâ€controlled, Noninferiority Study. Pain Practice, 2015, 15, 150-158.	0.9	11
196	Outcomes of Surgical Management of Men With Peyronie's Disease With Hourglass Deformity. Urology, 2016, 91, 119-123.	0.5	11
197	Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease. Urology, 2017, 106, 237.e9-237.e14.	0.5	11
198	The Use of Stromal Vascular Fraction in the Treatment of Male Sexual Dysfunction: A Review of Preclinical and Clinical Studies. Sexual Medicine Reviews, 2019, 7, 313-320.	1.5	11

#	Article	IF	CITATIONS
199	Insulin-Like Growth Factor-1–Loaded Polymeric Poly(Lactic-Co-Glycolic) Acid Microspheres Improved Erectile Function in a Rat Model of Bilateral Cavernous Nerve Injury. Journal of Sexual Medicine, 2019, 16, 383-393.	0.3	11
200	Feline penile erection induced by transurethral administration of sodium nitroprusside. Urological Research, 1999, 27, 432-436.	1.5	10
201	Does Lowering Hemoglobin A1c Reduce Penile Prosthesis Infection: A Systematic Review. Sexual Medicine Reviews, 2021, 9, 628-635.	1.5	10
202	Potassium channel agonists cause penile erection in cats. International Journal of Impotence Research, 1992, 4, 35-43.	1.0	10
203	Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan). International Journal of Impotence Research, 2004, 16, 73-77.	1.0	9
204	Inhibition of sympathetic neuroeffector transmission in human corpus cavernosum. BJU International, 2012, 110, 856-862.	1.3	9
205	Penile Priapism, Clitoral Priapism, and Persistent Genital Arousal Disorder: A Contemporary Review. Sexual Medicine Reviews, 2015, 3, 145-159.	1.5	9
206	Pioglitazone Enhances Survival and Regeneration of Pelvic Ganglion Neurons After Cavernosal Nerve Injury. Urology, 2016, 89, 76-82.	0.5	9
207	Collagenase <em>Clostridium histolyticum</em> in the treatment of Peyronie’s disease: patient selection and perspectives. Patient Preference and Adherence, 2017, Volume 11, 431-448.	0.8	9
208	Sildenafil's impact on male infertility: what has changed in 20 years?. International Journal of Impotence Research, 2019, 31, 71-73.	1.0	9
209	Male Genital Dermatology: A Primer for the Sexual Medicine Physician. Sexual Medicine Reviews, 2019, 7, 71-83.	1.5	9
210	The Management of Penile Fracture: a Review of the Literature with Special Consideration for Patients Undergoing Collagenase Clostridium Histolyticum Injection Therapy. Current Urology Reports, 2021, 22, 13.	1.0	9
211	Androgen deficiency in the aging male: Pathophysiology, diagnosis, and treatment alternatives. Current Urology Reports, 2001, 2, 473-479.	1.0	8
212	Using Wound Drains for the Uncomplicated Penile Prosthesis. Journal of Urology, 2011, 186, 1187-1189.	0.2	8
213	Surgery is not indicated for the treatment of premature ejaculation. Translational Andrology and Urology, 2016, 5, 607-612.	0.6	8
214	Analysis of the Symptomatology, Disease Course, and Treatment of Postorgasmic Illness Syndrome in a Large Sample. Journal of Sexual Medicine, 2020, 17, 2229-2235.	0.3	8
215	Application of Botulinum Neurotoxin in Female Sexual and Genitourinary Dysfunction: A Review of Current Practices. Sexual Medicine Reviews, 2021, 9, 57-63.	1.5	8
216	Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature. Current Urology Reports, 2021, 22, 6.	1.0	8

#	Article	IF	CITATIONS
217	Harnessing Stem Cell Potential for the Treatment of Erectile Function in Men with Diabetes Mellitus: From Preclinical/Clinical Perspectives to Penile Tissue Engineering. Current Stem Cell Research and Therapy, 2020, 15, 308-320.	0.6	8
218	Dapoxetine and the treatment of premature ejaculation. Translational Andrology and Urology, 2013, 2, 301-11.	0.6	8
219	Prosthetic urology: past, present, and future. Asian Journal of Andrology, 2020, 22, 1.	0.8	8
220	Drugs of the future for Peyronie's disease. Medical Hypotheses, 2012, 78, 305-311.	0.8	7
221	Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A â€~Real World' Clinical Perspective. Drugs, 2016, 76, 1523-1528.	4.9	7
222	Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie's disease. Translational Andrology and Urology, 2017, 6, 894-898.	0.6	7
223	Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now?. Sexual Medicine Reviews, 2021, 9, 320-330.	1.5	7
224	2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management. Current Pharmaceutical Design, 2015, 21, 1440-1454.	0.9	7
225	Premature ejaculation: do we have effective therapy?. Translational Andrology and Urology, 2013, 2, 45-53.	0.6	7
226	Three-piece inflatable penile prosthesis components (surgical pearls on reservoirs, pumps, and rear-tip) Tj ETQqO (	0 0 rgBT /0 1.0	Overlock 10 7
227	Characterization of Erectile Function in Monocrotaline-Treated Pulmonary Hypertensive Rats. Journal of Andrology, 2009, 30, 495-504.	2.0	6
228	Re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial. Eur Urol 2011;60:1105–13. European Urology, 2012, 61, e45-e46.	0.9	6
229	Activation of P2Y1 and P2Y2 nucleotide receptors by adenosine 5′-triphosphate analogues augmented nerve-mediated relaxation of human corpus cavernosum. Canadian Urological Association Journal, 2013, 3, 314.	0.3	6
230	Collagenase <i>Clostridium histolyticum</i> in the management of Peyronie's disease: a review of the evidence. Therapeutic Advances in Urology, 2016, 8, 192-202.	0.9	6
231	Benign Prostatic Hyperplasia Treatment Options and Their Effects on Sexual Function. Sexual Medicine Reviews, 2017, 5, 87-102.	1.5	6
232	Grower or shower? Predictors of change in penile length from the flaccid to erect state. International Journal of Impotence Research, 2018, 30, 287-291.	1.0	6
233	Pioglitazone's beneficial effects on erectile function preservation after cavernosal nerve injury in the rat are negated by inhibition of the insulin-like growth factor-1 receptor: a preclinical study. International Journal of Impotence Research, 2019, 31, 1-8.	1.0	6
234	Pharmacodynamics of the agents used for the treatment of erectile dysfunction. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 121-131.	1.5	6

#	Article	IF	CITATIONS
235	Clomiphene Citrate for Male Hypogonadism and Infertility: An Updated Review. Androgens: Clinical Research and Therapeutics, 2020, 1, 62-69.	0.2	6
236	Reviewing the evidence for shockwave- and cell-based regenerative therapies in the treatment of erectile dysfunction. Therapeutic Advances in Urology, 2021, 13, 175628722110020.	0.9	6
237	Revelations on Men Who Seek Penile Augmentation Surgery: A Review. Sexual Medicine Reviews, 2022, 10, 460-467.	1.5	6
238	Posttraumatic High Flow Internal Pudendal Artery-Urethral Fistula. Journal of Urology, 1995, 153, 734-736.	0.2	5
239	Treatment of premature ejaculation: new drugs and treatment strategies. Current Urology Reports, 2006, 7, 473-478.	1.0	5
240	New Concepts in the Diagnosis and Treatment of Premature Ejaculation. Current Urology Reports, 2010, 11, 414-420.	1.0	5
241	Retained Reservoirs of Inflatable Penile Prosthesis: A Systematic Review of the Literature and a Guide to Perioperative Management. Sexual Medicine Reviews, 2020, 8, 355-363.	1.5	5
242	A Systematic Review of Penile Prosthesis Surgery in Organ Transplant Recipients. Sexual Medicine Reviews, 2021, 9, 636-640.	1.5	5
243	Current Perspectives on Complications of Surgical Treatments forÂMale Stress Urinary Incontinence. Sexual Medicine Reviews, 2020, 8, 443-449.	1.5	5
244	Purinergic contraction of the rat vas deferens in L-NAME-induced hypertension: effect of sildenafil. Asian Journal of Andrology, 2010, 12, 415-421.	0.8	5
245	Functional measurements of penile erection in feline, canine and primate animal models. International Journal of Impotence Research, 2001, 13, 149-150.	1.0	4
246	Re: Treatment of Erectile Dysfunction in the Obese Type 2 Diabetic ZDF Rat With Adipose Tissue-Derived Stem Cells. European Urology, 2011, 59, 168-169.	0.9	4
247	Racial variations in response to intralesional collagenase clostridium histolyticum in men with Peyronie's disease. Translational Andrology and Urology, 2017, 6, 888-893.	0.6	4
248	Comparison of Adjuvant Radiation Therapy Before or After Artificial Urinary Sphincter Placement: A Multi-Institutional, Retrospective Analysis. Urology, 2018, 113, 160-165.	0.5	4
249	Testosterone Replacement Therapy. Scientific World Journal, The, 2004, 4, 142-149.	0.8	3
250	Testosterone Deficiency, Supplementation, and Prostate Cancer: Maintaining a Balanced Perspective. Journal of Sexual Medicine, 2013, 10, 2879-2881.	0.3	3
251	Pioglitazone prevents cavernosal nerve injury after radical prostatectomy. Medical Hypotheses, 2014, 82, 504.	0.8	3
252	Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact. Expert Opinion on Pharmacotherapy, 2016, 17, 2281-2289.	0.9	3

#	Article	IF	CITATIONS
253	Practice Patterns in the Diagnosis and Management of Hypogonadism: A Survey of Sexual Medicine Society of North America Members. Urology, 2017, 106, 87-95.	0.5	3
254	The Conception and Evaluation of Sexual Health Literature. Sexual Medicine Reviews, 2017, 5, 135-145.	1.5	3
255	Characterisation of pomegranate juice effects on human corpus cavernosum. Andrologia, 2017, 49, e12712.	1.0	3
256	Hematospermia Etiology, Diagnosis, Treatment, and Sexual Ramifications: A Narrative Review. Sexual Medicine Reviews, 2022, 10, 669-680.	1.5	3
257	Options for Masculinizing Genital Gender Affirming Surgery: A Critical Review of the Literature and Perspectives for Future Directions. Sexual Medicine Reviews, 2021, 9, 605-618.	1.5	3
258	Does erectile dysfunction drug use contribute to risky sexual behavior?. Asian Journal of Andrology, 2010, 12, 626-627.	0.8	3
259	Radical Prostatectomy and Other Pelvic Surgeries. , 2006, , 135-154.		3
260	Benign prostatic hyperplasia, sexual function, and overall evaluation of the male patient. Journal of the American Osteopathic Association, The, 2004, 104, S5-10.	1.7	3
261	Intranasal apomorphine. Nastech Pharmaceutical. IDrugs: the Investigational Drugs Journal, 2004, 7, 483-8.	0.7	3
262	The Role of Endothelium in Erectile Function and Dysfunction. , 2007, , 1541-1549.		2
263	1480 ONSET OF ACTION AND TIME TO EFFICACY OF AVANAFIL, A NOVEL, RAPID-ONSET PDE5 INHIBITOR IN MEN WITH MILD TO SEVERE ERECTILE DYSFUNCTION DATA FROM PHASE 2 AND PHASE 3 CLINICAL TRIALS. Journal of Urology, 2012, 187, .	0.2	2
264	Can Adipose-derived Stem Cells Be Used in the Treatment of Urethral Stricture Disease?. European Urology, 2016, 70, 1042-1043.	0.9	2
265	Vasectomy with vessel sealing device: comparison of different diameters. International Journal of Impotence Research, 2019, 31, 20-24.	1.0	2
266	The Role of Hormones in Male Sexual Function. Current Sexual Health Reports, 2020, 12, 101-112.	0.4	2
267	Updated Review of Testosterone Replacement Therapy in the Setting of Prostate Cancer. Androgens: Clinical Research and Therapeutics, 2021, 2, 36-45.	0.2	2
268	The molecular basis of erectile physiology: from bench to bedside. Journal of Andrology, 2002, 23, S3-4.	2.0	2
269	Are neutrophil–lymphocyte and platelet–lymphocyte ratios useful for determining active phase of Peyronie's disease?. Journal of Clinical Urology, 0, , 205141582210946.	0.1	2
270	Reply by the Author. Urology, 2009, 74, 1377-1378.	0.5	1

#	Article	IF	CITATIONS
271	Testosterone and the Prostate. Sexual Medicine Reviews, 2014, 2, 112-120.	1.5	1
272	Reply. Urology, 2015, 86, 299.	0.5	1
273	Diabetes and Sexual Function. Current Sexual Health Reports, 2016, 8, 9-18.	0.4	1
274	Re: Multicenter Investigation of the Micro-organisms Involved in Penile Prosthesis Infection: An Analysis of the Efficacy of the AUA and EAU Guidelines for Penile Prosthesis Prophylaxis. European Urology, 2017, 72, 854-855.	0.9	1
275	Complex penile prosthesis reservoir extraction: a case series. International Journal of Impotence Research, 2020, 32, 122-125.	1.0	1
276	Ivabradine, the hyperpolarization-activated cyclic nucleotide-gated channel blocker, elicits relaxation of the human corpus cavernosum: a potential option for erectile dysfunction treatment. Aging Male, 2020, 23, 1088-1097.	0.9	1
277	Re: Effect of Natesto on Reproductive Hormones, Semen Parameters and Hypogonadal Symptoms: A Single Center, Open Label, Single Arm Trial. European Urology, 2021, 79, 890-891.	0.9	1
278	Persistent Genital Arousal and Major Depressive Disorder in an Adolescent Male: Case Report and Discussion. Urology, 2021, , .	0.5	1
279	Intralesional Treatment of Peyronie's Disease. , 2007, , 81-92.		1
280	Available and future therapies for premature ejaculation. Drugs of Today, 2010, 46, 507.	0.7	1
281	Erectile dysfunction in the aging man: current options for treatment. Aging Health, 2006, 2, 71-86.	0.3	1
282	Commentary on "validation of robot-assisted vasectomy reversal". Asian Journal of Andrology, 2015, 17, 332.	0.8	1
283	Safety of penile prosthesis surgery in solid organ transplant patients. International Journal of Impotence Research, 2022, 34, 507-508.	1.0	1
284	RE: OPTIMIZING TREATMENT FOR DIABETES MELLITUS INDUCED ERECTILE DYSFUNCTION. Journal of Urology, 2004, 171, 1638-1639.	0.2	0
285	Controversies regarding testosterone supplementation in the prostate cancer patient. Current Sexual Health Reports, 2005, 2, 41-44.	0.4	0
286	Treatment of premature ejaculation: New drugs and treatment strategies. Current Sexual Health Reports, 2006, 3, 177-182.	0.4	0
287	Persistent penile abnormalities in men with Peyronie's disease. Nature Reviews Urology, 2006, 3, 634-635.	1.4	0
288	Controversies in the laboratory evaluation of hypogonadism: Androgen deficiency algorithm. Current Sexual Health Reports, 2007, 4, 51-55.	0.4	0

#	ARTICLE	IF	CITATIONS
289	Reply to Glorgio Pomara, Domenico Canale, Paolo Turchi and Francesco Francesca's Letter to the Editor re: Wayne J.G. Hellstrom, Marc Gittelman, Jonathan Jarow, et al. An Evaluation of Semen Characteristics in Men 45 Years of Age or Older after Daily Dosing with Tadalafil 20 mg: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, 9-Month Study. Eur Urol 2008;53:1058–65.	0.9	0
290	Introduction: centrally acting agents in male sexual dysfunction. International Journal of Impotence Research, 2008, 20, S1-S2.	1.0	0
291	Nursing practice: a primary care approach to intralesional injection therapy for Peyronie's disease. International Journal of Urological Nursing, 2008, 2, 78-84.	0.1	0
292	Diagnosis and Treatment of Male Ejaculatory Dysfunction. , 0, , 187-192.		0
293	Re: Long-Term Infection Outcomes After Original Antibiotic Impregnated Inflatable Penile Prosthesis Implants: Up to 7.7 Years of Followup. Journal of Urology, 2012, 187, 1936-1937.	0.2	0
294	Re: Prevalence of ejaculatory disorders in urban men-results of a random-sample survey. Andrologia, 2012, 44, 365-365.	1.0	0
295	Sirt3 modulation may be beneficial in the treatment of ejaculation dysfunction. Medical Hypotheses, 2013, 81, 448-449.	0.8	0
296	State of the art: medical treatment of Peyronie's disease. Expert Opinion on Orphan Drugs, 2013, 1, 867-876.	0.5	0
297	Re: Long-Term Infection Outcomes of 3-Piece Antibiotic Impregnated Penile Prostheses Used in Replacement Implant Surgery. Journal of Urology, 2013, 189, 1994-1996.	0.2	0
298	Collagenase clostridium histolyticum: a novel nonsurgical option for the treatment of Peyronie's disease. International Journal of Clinical Rheumatology, 2013, 8, 531-540.	0.3	0
299	Phosphodiesterase type 5 inhibitors for stuttering priapism: recent advances. Expert Opinion on Orphan Drugs, 2014, 2, 937-946.	0.5	0
300	Evaluation of collagenase Clostridium histolyticum for the treatment of Peyronie's disease. Expert Opinion on Orphan Drugs, 2015, 3, 1331-1338.	0.5	0
301	Intralesional collagenase clostridium histolyticum study provides real-world analysis. Translational Andrology and Urology, 2016, 5, 951-952.	0.6	0
302	Semen proteome alterations in the smoking male: a nonâ€generalizable study. BJU International, 2016, 118, 673-674.	1.3	0
303	Injection Therapy for Peyronie's Disease. , 2016, , 301-313.		0
304	Immediate Placement of Penile Prosthesis for the Management of Ischemic Priapism as First-line Treatment. European Urology Focus, 2019, 5, 531-532.	1.6	0
305	Tips and tricks in the management of inflatable penile prosthesis infection: A review. Arab Journal of Urology Arab Association of Urology, 2021, 19, 346-352.	0.7	0
306	Re: Testosterone Therapy in Men with Biochemical Recurrence and Metastatic Prostate Cancer: Initial Observations. Androgens: Clinical Research and Therapeutics, 2021, 2, 129-130.	0.2	0

#	Article	IF	CITATIONS
307	Neophallus Construction and Penile Prosthesis Implantation: Techniques and Complications. Current Sexual Health Reports, 2021, 13, 117-127.	0.4	Ο
308	Medicolegal Impacts of Penile Implant Surgery. , 2022, , 247-258.		0
309	Considerations on Inflatable Penile Prosthesis Reservoir Placement. , 2022, , 79-96.		0
310	Medical Management of Peyronie's Disease. , 2012, , 429-437.		0
311	The Clinical Diagnosis of Androgen Deficiency. , 2013, , 33-39.		0
312	Current state of affairs of Peyronie's disease. Translational Andrology and Urology, 2016, 5, 278-279.	0.6	0
313	Strategic Therapies for Ejaculatory Disorders and Erectile Dysfunction in the Infertile Man. , 2005, , 169-181.		0